Abstract: The present invention relates to a cosmetic composition containing a unique polymer blend, which includes: (a) a first polymeric film-former having a first glass transition temperature ranging from about ?20° C. to about 0° C.; (b) a second polymeric film-former having a second glass transition temperature that is at least 50° C. higher than the first glass transition temperature; and (c) a third cross-linked polymeric film-former. The cosmetic composition of the present invention can be applied to human skin or keratinous fibers for forming a film thereon with exceptionally long wearability, reduced flaking and smudge properties, and good removability by warm water.

Abstract: The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions.

Abstract: The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Abstract: A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation.

Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The invention “colloidal nanoscale carriers for active hydrophilic substances and method for producing same” pertains to the field of medical, odontological or hygiene preparations, and is characterized by structures formed by hydrophilic polymers that contain active hydrophilic substances coated with a non-hydrophilic phase and surfactants with affinity for the components, forming an invert emulsion that allows the incorporation and controlled delivery of active hydrophilic substances, conferring properties such as protection against degradation processes, improvement of compatibility with the other components of the formulation in the final product, increase in the availability and/or bioavailability of the active substance in the medium of interest (including improvements in permeation processes in biological materials, reduction of the exposure and volatilization of the active substance in the medium) and controlled release of the active substance(s).

Abstract: A Gantrez hydrogel comprising sodium, calcium, zinc, strontium, and ferric cations, and a polyvinylpyrrolidone based tack agent is disclosed. A method for preparation of the Gantrez hydrogel is also disclosed.

Abstract: Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.

Abstract: Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO2 in their environment, thus regulating release of an entrapped drug.

Abstract: A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.

Abstract: A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

Abstract: A solid formulation comprising a water-soluble drug and a hardly water-soluble pharmaceutically-acceptable solid substance, which comprises silicone as a carrier, wherein the silicone formulation can exhibit an excellent controlled-release of the water-soluble drug.

Abstract: Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.

Abstract: The present invention relates to a use of a copolymer comprising N-vinyllactam, and vinylimidazol or a quaternized vinylimidazol in polymerized form as dispersing agent in an aqueous composition containing a water-insoluble pesticide. Further on, it relates to an aqueous composition which contains a copolymer comprising in polymerized form at least 20 mol % N-vinyllactam, and at least 1 mol % vinylimidazol or a quaternized vinylimidazol, a water-insoluble pesticide, and a dissolved salt. The invention also relates to a method for preparing the said composition by mixing water, the water-insoluble pesticide, the salt and the copolymer.

Abstract: Disclosed are organogels comprising selected amounts of 12-hydroxystearic acid gelator, cosmetically acceptable oil, a copolymer that carries at least 70% by weight of the copolymer of pendant alkyl groups having chain length of C12-C24, and, optionally, co-structurant; also disclosed are cosmetic compositions that comprise such organogels.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

Abstract: The present invention relates to a thickener comprising i) at least one c onic polymer preparable by polymerization of a) at least one water-soluble ethylenically unsaturated monomer comprising at least one cationic monomer, optionally at least one anionic monomer and/or. optionally at least one nonionic monomer, b) at least one e,(hylenically unsaturated associative monomer, c) optionally at ieast one crosslinker, d) optionally at least one chain transfer agent, ii) at least one activator, where the ratio of activator to cationic polymer is >10 to 100 [% by weight/% by weight].

Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.

Abstract: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivaties like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.

Abstract: Provided is a water dispersion type sex pheromone sustained release preparation which makes it possible to suppress excess release at the initial stage of spraying and release a sex pheromone substance at a constant amount for a predetermined period, and which can be sprayed by using a common sprayer. Specifically provided is a water dispersion type sex pheromone sustained release preparation, comprising an insect sex pheromone substance which is enclosed in a ring of a cyclodextrin, an inclusion cyclodextrin which encloses the insect sex pheromone substance, a non-inclusion cyclodextrin which does not enclose the insect sex pheromone substance, a water-soluble polymer, and water.

Abstract: In one embodiment, a method includes making a pteredin phenyl pentanedioic (3P) formulation by providing an aqueous solution including one of more 3P molecules neutralized with one or more of an alkali, an alkali earth metal hydroxide, or an alkali carbonate; adding to the aqueous solution one of a surfactant, dispersant, or additive with the guest molecules; and non-covalently crosslinking the 3P formulation by exposing the 3P formulation to an excess solution of multivalent cation salt.

Abstract: The present invention relates to cosmetic or dermatological formulations comprising at least one active compound, at least one polymer which is molecularly imprinted in the presence of this active compound and at least one fatty phase.

Abstract: A method of forming particles, comprises accelerating a first stream comprising a first liquid, applying a charging voltage of at most 1.5 kV to the first stream, and vibrating the first stream, to form particles.

Abstract: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound.

Abstract: Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a variety of high-molecular weight polymeric compounds and include substantial levels of water to improve skin tolerance by the patient. The transdermal patches may also include transcutol as a solvent for the drug, which has been found to increase the effectiveness of drug delivery. The present disclosure also provides for methods of loading a drug into a transdermal formulation after the crosslinking of the hydrogel, thus improving stability and bioavailability through avoiding exposure of the drug to the radiation used in the crosslinking procedure.

Abstract: The present invention is directed to stable emulsions comprising polyolefins, in particular polyisobutene, the process to obtain said emulsions and the use of said emulsions.

Abstract: The invention provides a method for preparing a hydrogel from a hydrophilic polymer having one or more functional groups which are capable of co-reacting in a condensation reaction which method comprises the steps of: (i) preparing a solution of the polymer; (ii) heating the solution to a temperature sufficient for the condensation reaction to take place for a period of time sufficient for the hydrogel to cross-link wherein where the hydrophilic polymer comprises a first and a second hydrophilic polymer, step (i) comprises a step of mixing the hydrophilic polymers to prepare a homogeneous intimate mixture of the polymers; and wherein the heating step (ii) is carried out at a pressure greater than atmospheric pressure. The method of the invention is advantageous because it is relatively low cost, it is a safer procedure with less health & safety concerns, it is carried out in a liquid state and is not limited by film thickness.

Abstract: It is intended to avoid dose dumping of a drug and improve the dissolution properties of a drug in the lower gastrointestinal tract, and thereby provide a sustained-release solid preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release solid preparation containing (A) a pharmacologically active drug, (B) carboxyvinyl polymer, (C) povidone, and (D) carmellose sodium, xanthan gum, or sodium carboxymethyl starch.

Abstract: The present invention relates to a method for preparing nano-particles, and more particularly, to a method for preparing nano-particles containing active materials in a simple and highly efficient manner through a grinding process.

Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.

Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.

Abstract: The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to anemulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C1-C6) alkyl esters of the aforementioned acids, or mixtures thereof, and wherein the oil phase comprises at least one membrane-forming substance forming a lamellar arranged membrane in the emulsion.

Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.

Abstract: The present invention relates to a cosmetic composition containing a unique polymer blend, which includes: (a) a first polymeric film-former having a first glass transition temperature ranging from about ?20° C. to about 0° C.; (b) a second polymeric film-former having a second glass transition temperature that is at least 50° C. higher than the first glass transition temperature; and (c) a third cross-linked polymeric film-former. The cosmetic composition of the present invention can be applied to human skin or keratinous fibers for forming a film thereon with exceptionally long wearability, reduced flaking and smudge properties, and good removability by warm water.

Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Abstract: A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

Abstract: Disclosed is a manufacturing method for a fine powder exhibiting improved solubility, little impurity contamination, and a high recovery rate. Material to be ground and a grinding medium are suspended and stirred in a liquefied inert gas dispersion medium such as dried ice, and the material to be ground is made into a sub-micron or nano-sized fine powder. A uniform fine powder can be obtained when the material to be ground is a mixture having two or more components. Impurity contamination can be reduced by using granular dry ice as the grinding medium.

Abstract: An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially gels) after dispensing of the composition to the eye to provide extended viscosity enhancement of the composition.

Abstract: This invention relates to a tissue expander for use in medical, veterinary and dental applications. The tissue expander comprises a self-inflating polymer network and a biodegradable polymer having a non-degraded state and a degraded state which in the non-degraded state constrains the inflation of the self-inflating polymer network and in the degraded state allows inflation of the self-inflating polymer network. In a preferred embodiment, the self-inflating polymer network and the biodegradable polymer form an interpenetrating polymer network or a semi-interpenetrating polymer network. Alternatively or in addition, the self-inflating polymer network forms a core and the biodegradable polymer forms coating which partially or fully surrounds the core.

Abstract: The invention encompasses formulations for increased attachment and retention systems of biologically active organic compounds and methods for the preparation and use thereof.

Abstract: The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly suitable for the production of medicaments based on active ingredients which have low solubility or very low solubility in water or which are virtually insoluble in water.

Abstract: The present invention relates to a method for preparing an oral lyophilizate composition comprising: a) forming a liquid phase by using at least one homogenising agent having tensioactive properties, said liquid phase comprising at least an active pharmaceutical ingredient, a filler and/or a binding agent and a solvent, b) lyophilizing said liquid phase to form the oral lyophilizate composition.

Abstract: The invention relates to a foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (M1) and at least one further monomer.

Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.

Abstract: A personal health care article. More particularly, a personal health care article comprising at least one porous disintegratable solid substrate comprising: from about 1% to about 70%, by weight of said substrate, of a surfactant, from about 10% to about 70%, by weight of said substrate, of one or more polymers, from about 0.025% to about 85%, by weight of said substrate, of one or more health care actives, optionally a plasticizer, and optionally an aesthetic agent wherein said article is ingestible. The invention also comprises a process for making a personal health care article.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10?7 reciprocal second.